Details of the Drug

General Information of Drug (ID: DMCSLZ4)

Drug Name
Sodium zirconium cyclosilicate
Synonyms UZSi 9; ZS-9 compound; Sodium zirconium silicate (Na2ZrSi3O9); UZSi-9; CBTCHTJSGLCFMY-UHFFFAOYSA-N; 543686-27-7
Indication
Disease Entry ICD 11 Status REF
Hyperkalemia 5C76 Approved [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
1		 Molecular Weight 371.5
Topological Polar Surface Area Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 6
Hydrogen Bond Acceptor Count 9
Chemical Identifiers
Formula
H6Na2O9Si3Zr+2
IUPAC Name
disodium;2,2,4,4,6,6-hexahydroxy-1,3,5,2,4,6-trioxatrisilinane;zirconium
Canonical SMILES
O[Si]1(O[Si](O[Si](O1)(O)O)(O)O)O.[Na+].[Na+].[Zr]
InChI
InChI=1S/2Na.H6O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/h;;1-6H;/q2*+1;;
InChIKey
CBTCHTJSGLCFMY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
91799284
CAS Number
17141-74-1
DrugBank ID
DB14048
TTD ID
D03AZK

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Potassium (K) TTB0SC6 NOUNIPROTAC Binder [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8.